Why the study?
Cardiovascular risk in girls and women remains underrecognized and underaddressed, particularly regarding female-specific sex hormone exposure and fragmented care across specialties. A unified life course approach addressing the interconnectedness of hormonal, psychosocial, and cardiovascular health was needed.
This multiorganizational presidential advisory establishes a Female Life Stage framework to unify and optimize the screening, prevention, and management of cardiovascular disease across the female life course.
Cardiovascular disease is the leading cause of morbidity and mortality in women, contributes markedly to healthcare expenditures, and is projected to increase substantially by 2050 if current trends continue. There is growing recognition of the complex role of sex as a biologic variable and its influence on cardiovascular health and disease. However, cardiovascular risk remains underrecognized and underaddressed in girls and women, particularly as it relates to female-specific exposure to sex hormones (both endogenous and exogenous), which are systemic modulators of cardiovascular biology. Moreover, girls and women uniquely experience fragmented care spanning specialties, including pediatrics, adolescent medicine, primary care, obstetrics and gynecology, maternal-fetal medicine, cardiology, endocrinology, hematology, and neurology. Consequently, there is a need for a unified life course approach that addresses the female-specific interconnectedness of hormonal, psychosocial, and cardiovascular health. To address these gaps, the American Heart Association, in collaboration with the American Academy of Pediatrics, American College of Obstetricians and Gynecologists, and Society for Maternal-Fetal Medicine, established a Female Life Stage framework to optimize the prevention and management of cardiovascular disease in girls and women. Physiologic changes in sex hormones define clinically distinct life stages (ie, perimenarche, ovarian cycling, perimenopause, postmenopause), which directly inform female-specific considerations for screening, prevention, and management of cardiovascular disease. This presidential advisory details the framework and its scientific rationale, highlights opportunities for implementation across settings, and identifies priorities for research, clinician education, patient advocacy, and policy. This framework offers a transformative opportunity to equitably improve cardiovascular health for all girls and women.
No takes yet. Share an insight, caveat, or question.
Khan et al. (2026) conducted a review in Cardiovascular disease. Female Life Stage framework was evaluated. The Female Life Stage framework establishes a unified life course approach across perimenarche, ovarian cycling, perimenopause, and postmenopause to optimize CVD prevention and management in women.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: